Traumatic Brain Injury: What Is a Favorable Outcome?
- PMID: 34861770
- PMCID: PMC9248332
- DOI: 10.1089/neu.2021.0356
Traumatic Brain Injury: What Is a Favorable Outcome?
Abstract
Traumatic brain injury (TBI) results in disparate outcomes ranging from persistent disorders of consciousness to symptom resolution. Despite the breadth and complexity of TBI recovery, most clinical trials dichotomize outcome by establishing an arbitrary cut-point, above and below which recovery is described as "favorable" and "unfavorable," respectively. For example, the widely used eight-level Glasgow Outcome Scale-Extended (GOSE) is typically collapsed into these two categories. Dichotomizing the GOSE into "favorable" and "unfavorable" outcome may limit detection of treatment effects in TBI clinical trials, contribute to imprecise prognostic counseling, and unduly influence decision-making with regard to withdrawal of life-sustaining therapy. We illustrate the lack of standardization in defining "unfavorable" and "favorable" TBI outcome on the GOSE by identifying the broad range of cut-points, from a score of 3 (part-time supervision in the home required) to 7 (presence of some residual of symptoms), that have been used to dichotomize the GOSE. We also highlight the ethical concerns related to characterizing TBI outcomes solely from the perspective of investigators and clinicians, rather than patients and caregivers. Finally, we suggest that a pragmatic, immediate solution to GOSE dichotomization is to report the likelihood of achieving each of the eight GOSE outcome levels and propose a study design for a new patient- and caregiver-centered TBI outcome metric.
Keywords: Glasgow Outcome Scale; outcome; traumatic brain injury.
Conflict of interest statement
Y.G. Bodien reports funding from National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (U01 NS1365885, U01-NS086090), National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DPCP0008-01-00, 90DP0039), James S. McDonnell Foundation, and Tiny Blue Dot Foundation.
J.T. Giacino reports funding from NIH National Institute of Neurological Disorders and Stroke (U01-NS086090, UH3NS095554), U.S. Department of Defense (W81XWH-14-2-0176), National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DPCP0008-01-00, 90DP0039)
For D.A. Zuckerman, no competing financial interests exist.
References
-
- Wilson, J.T., Pettigrew, L.E., and Teasdale, G.M. (1998). Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J. Neurotrauma 15, 573–585. - PubMed
-
- McMillan, T., Wilson, L., Ponsford, J., Levin, H., Teasdale, G., and Bond, M. (2016). The Glasgow Outcome Scale—40 years of application and refinement. Nat. Rev. Neurol. 12, 477–485. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
